HuiGene Therapeutics Closes $400M Series B Financing

(VCBeat) May. 17, 2021 -- Huida (Shanghai) Biotechnology Co., Ltd. ("HuiGene Therapeutics"), a gene-editing tool developer, recently announced it has closed 400 million yuan in Series B financing from a number of global well-known funds. The funding will be used to support the company's technological innovation, preclinical development and registration of its products, the construction of a drug discovery pilot platform, and the improvement of its manufacturing and clinical development teams.

Previously, HuiGene Therapeutics completed the ￥30 million angel round of financing in November 2018 and the Series A financing of over 100 million yuan in December 2019. For the company's information and product pipeline, please go and check the official website of HuiGene Therapeutics.

Founded in October 2018 in Shanghai, HuiGene Therapeutics is an innovative biopharmaceutical company focusing on gene editing technology and gene therapy drug development. The company has the world's leading RNA editing technology and preclinical research and development platform of gene therapy, covering neurodegenerative diseases, visual disorders, hearing disorders and other diseases.

HuiGene Therapeutics has brought together the world's top talents in the early-stage development of innovative drugs, clinical research and commercialization. The company is improving the drug discovery & production and clinical medicine team at the same time, hoping to make gene therapy benefit millions of patients in the near future, and become the world's leading biopharmaceutical company.

Dr. Yao Xuan, the founder and chief executive of HuiGene Therapeutics, said, "less than three years after HuiGene Therapeutics being founded, relying on the strong team of R&D and innovation, as well as the deep understanding of gene editing for treatment, the company has built the comprehensive technology platform covering gene editing, delivery carriers, animal disease model and drug development.At the same time, several pipelines have shown very positive preclinical research results and smoothly entered the clinical stage."